Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Bad news for 88E but good news for ZPHR since they will be one of leading lights very shortly
https://www.moex.com/en/issue.aspx?board=TQBR&code=POLY&utm_source=www.moex.com&utm_term=poly
Currently 920 Rouble @ GBPRUB c.115 - £8 being paid on MOEX
https://www.moex.com/n45930/?nt=201
On 29 March 2022, the Moscow Exchange markets will operate as follows as decided by the Bank of Russia.
Equity Market
all Russian stocks and international securities from the MOEX Russian Index will be available for trading in the Main Trading Mode (central order book) (9:50-10:00 opening auction, 10:00-13:40 trading period, 13:40-13:50 closing auction) from 9:50-13:50 Moscow time, and for negotiated trades/negotiated trades with the CCP from 9:50-19:00; short sales in stocks are not allowed,
https://www.standard.co.uk/news/uk/vladimir-putin-liz-truss-volodymyr-zelensky-russian-foreign-secretary-b990685.html?msclkid=00ce296eaea311ec809fd63ddb23c554
"Sanctions against Russian oligarchs, banks and businesses could be lifted if Vladimir Putin ends his invasion of Ukraine and commits to “no further aggression”, Liz Truss has said.
The Foreign Secretary said in an interview published on Sunday that the threat of “snapback sanctions” would be retained if the Russian president did attack again.
Ms Truss told the Sunday Telegraph that a “negotiations unit” had been established in the Foreign Office to aid possible peace talks.
With the Kremlin’s troops struggling, her comments will be seen as a possible incentive for Mr Putin to cut his losses and broker a deal with Ukraine.
Moscow has given indications after a month of war that it might scale back its ambitions to fight for control of the Donbas region in the east of Ukraine."
My last two tests boxes delivered by gov portal were Innova. To me that suggests Govt are using up known bad tests and not ordering more half way decent ones. Yet covid is now rife. In meantime no news from Diagnostics division. Are they keeping their powder dry???
Thanks Jasper13 for that analysis. Taking it a bit further and a bit more conservatively re revenues in 2022 and 2023
. say new flow rates, ex fracking, are a little less than you project so revenue pa of $5-7m. So for balance of year rev of $3.5-5m
. say refrac allows 3x flow rates so rev pa of $15-21m or $4-5m rev in 2022 once refrac is operational in Q4
. total rev in 2022 $7.5m-10m
. rev in 2023 from initial two wells $15-21m plus two new frac wells from Q2 - potentially with JV, say 50% share of revenue, or c.$5m-7m extra. Total revenue for 2023 c.$20-28m.
. rev in 2024, ex any further expansion, $22-31mm
. re further expansion of basin using fracking - this will surely happen as revenues flow.
So a few weeks to initial revenue then ever escalating revenue flows thereafter in a reasonable timeframe. IMO SP will rerate strongly from April onwards as revenues come in.
In last years annual report issued April 22nd there is a section on Bispecifics which I've not seen discussed in any detail to date.
https://www.lse.co.uk/rns/AVCT/final-results-2zzedbl7989p4s0.html
"Building a pre-clinical pipeline of valuable chemotherapy/immunotherapy drug assets
In the oncology field it has become clear in recent years that cancer immunotherapies used singly, so-called 'monotherapies' have limited overall response rates and that combining immune checkpoint modulators such as PD-1, or PD-L1, with chemotherapy improves patients' outcomes. Avacta is in a unique position, with two proprietary platforms, to address this urgent clinical need.
The Company's strategy is to harness the benefits of the Affimer® platform to build single Affimer® drug molecules that can hit two drug targets simultaneously, called 'bispecifics', and to bring together Affimer® immunotherapies with the pre|CISION™ targeted chemotherapies, in order to develop superior cancer treatments with better patient outcomes."
We of course await AVA6000 results and are pleased with AVA3996 as next FAP drug. These are monotherapies. AVACTA have a pipeline of further monotherapies with a tgt mkt of $56bln. In addition to this there is the Bispecifics programme which I haven't seen a tgt mkt figure for but imagine is also collosal.
This years annual report should provide more detail on Bispecifics progress. IMO this is another catalist for the SP.
In case you haven't seen details of the AVA6000 trial and also want to monitor progress. Have a look at the outcomes targeted and then ask yourself if those outcomes are positive even at Phase 1a what implications for the SP are.
https://clinicaltrials.gov/ct2/history/NCT04969835?V_4=View#StudyPageTop
Risen above 200EMA with SSL Hybrid and QQE showing buy signals for 1st time since early Dec
I've mentioned on another board that looking for uncorrelated stocks is what I try to do in times like these. SNG is uncorrelated to current events. We await clarification as to how hospital administered steroids affected the SPRINTER trials and how that likely will not be the case in the ACTIV-2 trials which are being done at home and will be a better demonstration of SNG. ACTIV-2 trials started some while back and interim results are due at any time. Also remember the number of deaths even when using steroids was markedly improved with SNG in the SPRINTER trial. Polygon have averaged down since they have a longer timeframe than most PI's. With current events SNG at this SP is a good uncorrelated investment.
In times like these I always look for uncorrelated stocks, or far as is possible, to current events. AVCT is uncorrelated since it is focused on a disease that will be with us forever. Great stock to be in as evidenced by SP today.
At the moment AVA6000 is being trialed at
Royal Marsden (London); St James (Leeds) & The Christie (Manchester)
to come are:
The freeman (Newcastle; Weston Park Cancer Centre (Sheffield) & The Beaston (Glasgow) in UK
Two sites in US once US trials start as approved last November by FDA.
More patients, more data, more confirmation that trials are working satisfactorily at preliminary sites.
So lots of news to come. Further details on the trials can be found at
https://www.clinicaltrials.gov/ct2/show/NCT04969835
DYOR please.
IMO we will have positive movement in SP well before summer from one or more of the following
. more AVA600 trial sites (UK & USA)
. AVA6000 Dose escalation - possibly two more times
. 3996 pre-clinical package
. YE results end of April (last year on April 22nd)
. II's beginning to buy - currently 64% of shareholding is II's and most have not sold
. Surprise diagnostics news - improbable but not impossible
Firm HOLD for me.
I understand the disappointment that jam won't be tomorrow re Sprinter trials. However, RNS clearly shows significant reduction in deaths and importance of ACTIV2 trials that have a larger cohort and are more important in the US given huge costs of hospital treatment in the US. Pharma's trial drugs to better understand application and efficacy - this isn't an all or nothing process. My own view is SP has fair value some way north of where we are today.
My take is that CPR will take us to 7p and then further news as Tim outlines above to c. 10p over the next months then as 3 drills at PB take shape CPR will be revised upwards with more proven reserves so onto 15p by year end. Nice and steady great investment.
What do others think?
https://www.hl.co.uk/news/2022/2/17/spotify-acquires-podsights-and-chartable-to-advance-its-podcasting-business?utm_campaign=Newsroom&utm_source=AdobeCampaign&utm_medium=email&theSource=EONRM&e_cti=6934118&e_ct=T&Override=1&deliveryName=DM6883
Spotify Inc deepened its investment in podcasting with the acquisitions of Podsights and Chartable, two services that provide greater insights for advertisers and podcasting publishers, the Swedish company said on Wednesday.
Podsights helps marketers gauge the effectiveness of their ads, one area that Spotify said has been a major challenge. Chartable provides audience insights that help podcast publishers measure the effectiveness of their growth campaigns.
Two acquisitions for podcast analysis. Now acquisitions for more content - BOOM!
On ORTEX platform II's are 64% with no II sales since last September when 350k sold by Ruffer LLP. Short sellers Jupiter have 1.1% and Bronte Capital 0.53%. Rest is PI's.
Pretty clear what is happening - money moving from the weak to the strong.
If you can bear the stress, me included, HOLD on tight. CSO interview last week gave very clues that AVA6000 is working far better than they can disclose officially.
Some key comments i picked up outside of slide pack and ROSS
1. Mention of 37000 acres as current paradox holding. Implying are looking to add more as they did last year. Also comparing Paradox to other US prolific reserves mentioned a few times again implies they would be supported by Utah state to lease more. Overall reserves can therfore only increase significantly beyond current incoming CPR
2. Directors could not participate in latest equity raise because of knowledge of incoming CPR details. Sounds very positive IMO. Noting of course that since they couldn't participate CH and other directors have been diluted too
3. But, cash flow per share will improve twofold which is a major measure of company valuation so the dilution wad worth it
4. Plenty of hints that CPR will be very positive in flexion point.
Aside from that very professional presentation by CH.
Well said.. who deramps a holding of his supposed size??
A £28 trade at .95 to trick unaware PI's! Sickening trading manipulation.